Investor Update

Basel, 26 June 2012

Anti-Cancer Agent “Tarceva®”, Application for Approval of Additional Indication of Non-Small Cell Lung Cancer (First Line Therapy)

Dear Investor,

Please find attached a press release by Chugai:

http://www.roche.com/inv-update-2012-06-26c-annex.pdf